Lupin 's subsidiary Multicare Pharmaceuticals Philippines (MPPI) has executed a substantial share buyback program, repurchasing 2,813,811 shares from existing shareholders. The transaction was disclosed through a regulatory filing under Regulation 30 of the SEBI Listing Regulations, with the buyback completed using MPPI's retained earnings.

Share Buyback Transaction Details

The buyback has resulted in a significant ownership restructuring within the Philippines-based pharmaceutical subsidiary. Nanomi B.V., Netherlands, which is a wholly owned subsidiary of Lupin, did not participate in the buyback process, leading to an automatic increase in its proportional shareholding.

MPPI Financial Performance

Multicare Pharmaceuticals Philippines, incorporated in November 2001, operates in trading, importing, marketing, and distributing pharmaceutical products and medical devices. The company has demonstrated consistent operational performance with varying revenue trends over recent years.

Regulatory Compliance

The transaction has been properly disclosed pursuant to Regulation 30 read with Schedule III of the SEBI Listing Regulations. The buyback does not fall within the purview of related party transactions, and no promoter or group companies have any interest in the transaction. The ownership change became effective immediately upon completion of the buyback process.

Strategic Impact

This corporate action strengthens Lupin's control over its Philippines operations through increased subsidiary ownership. The buyback represents efficient capital allocation within MPPI while enhancing Nanomi's strategic position in the Philippine pharmaceutical market without requiring additional investment from the parent entity.

Lupin Limited announced a significant regulatory achievement, receiving tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Pitolisant Tablets. This approval marks another milestone in the company's expanding generic pharmaceutical portfolio and strengthens its presence in the central nervous system therapy segment.

FDA Approval Details

The U.S. FDA has granted tentative approval for Lupin's Abbreviated New Drug Application covering Pitolisant Tablets in two strengths. The regulatory approval encompasses specific dosage forms and manufacturing specifications that align with established pharmaceutical standards.

Manufacturing and Production

The approved Pitolisant Tablets will be manufactured at Lupin's Nagpur facility in India, leveraging the company's established manufacturing capabilities and quality systems. This facility represents part of Lupin's global manufacturing network, which includes 15 state-of-the-art manufacturing sites worldwide.

The bioequivalence designation confirms that Lupin's generic formulation demonstrates comparable therapeutic efficacy to the reference product Wakix®, manufactured by Bioprojet Europe, Ltd. This approval allows Lupin to offer a generic alternative for the indication specified in the approved labeling.

Company Profile and Market Position

Lupin Limited operates as a global pharmaceutical leader headquartered in Mumbai, India, with products distributed across over 100 markets worldwide. The company maintains a diversified portfolio spanning multiple therapeutic areas including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health.

The company's operational infrastructure includes 7 research centers globally and employs over 22,000 professionals. Lupin's business segments encompass branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients, supported by subsidiaries including Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

Regulatory Compliance

This announcement was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure ensures transparency for stakeholders regarding material developments that may impact the company's business operations and market position.